Currentblue cross blue shield - louisianaPolicy AHS - G2011

Diagnostic testing of iron homeostasis metabolism pdf

Defines coverage and non-coverage criteria for laboratory tests of iron homeostasis and metabolism (primarily serum ferritin and transferrin saturation), lists limitations (frequency), and states tests that do not meet coverage (hepcidin, GlycA). Applies to Blue Cross and Blue Shield of Louisiana members per benefit coverage.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyG2011 diagnostic testing of iron homeostasis metabolism pdf

Policy CodePolicy AHS - G2011

Change TypeMaterial edits to frequency rules, added indications, and explicit exclusions

Effective DateMay 15, 2026

Next Review Date

Key ActionProviders must document that testing meets one of the listed covered indications and ensure testing frequency follows policy-specified limits.

SourceLink

POLICY UPDATE CHANGES

CC1: added '(no more than one test per month unless otherwise specified)'.

CC1.b edited to add frequency: 'Once every three weeks for individuals with an iron overload disorder.'

CC1.h edited to include CKD-dependent frequencies: 'One test every three months if not receiving dialysis; One test every month if receiving dialysis.'

Added CC1.j: 'For individuals with restless legs syndrome or periodic limb movement disorder.'

Added CC2.d: 'For individuals with restless legs syndrome or periodic limb movement disorder.'

CC3 clarified that testing outside addressed conditions is not allowed, including testing of asymptomatic individuals.

CC4: 'Serum hepcidin testing, including immunoassays, DOES NOT MEET COVERAGE CRITERIA.'

Administrative and reference updates: background, guidelines, and evidence-based scientific references updated across multiple review dates.

Primary covered test categories (ferritin, transferrin saturation)

2Tests explicitly not covered (hepcidin, GlycA)

2CKD monitoring frequency variants

3Key frequency rules added/edited

MultipleGuideline sources summarized

5Procedure Codes listed

Coverage Summary

Scope: This policy defines coverage and non-coverage criteria for laboratory testing of iron homeostasis and metabolism for Blue Cross and Blue Shield of Louisiana members (Policy ID: AHS - G2011). The primary tests addressed are serum ferritin and transferrin saturation, with specified frequency limits and clinical indications. The policy also lists tests that DO NOT MEET COVERAGE CRITERIA, including serum hepcidin testing (including immunoassays) and the use of GlycA to measure or monitor transferrin or other glycosylated proteins.

Overview: Measurement of serum ferritin and transferrin saturation (TSAT) is covered when performed for specified clinical indications (e.g., anemia, evaluation of iron overload/hemochromatosis, first-degree relatives with hereditary hemochromatosis, liver disease, HLH/Still disease, male secondary hypogonadism, chronic kidney disease monitoring with CKD-specific frequencies, iron therapy monitoring, and restless legs syndrome/periodic limb movement disorder). General frequency limits include a policy-wide cap of no more than one ferritin test per month unless otherwise specified, with explicit exceptions: once every three weeks for iron overload disorders and CKD-specific schedules (every three months if not on dialysis; monthly if receiving dialysis). Claims for ferritin or transferrin/TSAT testing outside the listed indications, including testing of asymptomatic individuals, do not meet coverage criteria.

Key thresholds and limits

Ferritin frequency general limitNo more than one test per month unless otherwise specified

Ferritin - iron overload disorderOnce every three weeks

Ferritin - CKD (not on dialysis)One test every three months

Ferritin - CKD (receiving dialysis)One test every month

Ferritin low threshold (iron deficiency)Low SF <30 µg/L is sensitive and specific for iron deficiency; AGA recommends 45 ng/mL cutoff over 15 ng/mL in patients with anemia

KDIGO withholding ironWithhold iron if ferritin ≥700 ng/mL or TSAT ≥40%

AASM RLS/PLMD thresholdsSupplement if ferritin ≤75 ng/mL or TSAT <20%; IV only if ferritin 75–100 ng/mL

Stats - evidence references countMultiple guideline and evidence references cited (references 86-116 and others)

Stats - explicitly not covered tests2 tests explicitly not covered (hepcidin, GlycA)

Medical-Necessity Criteria

Measurement of serum ferritin levels

Measurement of serum ferritin levels (no more than one test per month unless otherwise specified) MEETS COVERAGE CRITERIA in any of the following situations:

ANY of the following

For individuals with anemia.
Once every three weeks for individuals with an iron overload disorder.
Frequency limit: once every 3 weeks for iron overload disorders.
For individuals with symptoms of hemochromatosis (see Note 1).
For individuals with first-degree relatives (see Note 2) with confirmed hereditary hemochromatosis (HH).

Not Medically Necessary / Experimental

Other situations for ferritin or transferrin testing

Tests not listed above

ALL of the following

For all other situations not addressed above, measurement of ferritin or transferrin levels, including transferrin saturation, DOES NOT MEET COVERAGE CRITERIA.
CC3: prohibition on testing outside addressed conditions
Testing of asymptomatic individuals is not allowed.
clarified exclusion for asymptomatic screening

Uncovered tests

ANY of the following

Coding

Applicable CPT/HCPCS Procedure Codesmixed

No codes listed

Applicable CPT/HCPCS Procedure Codes (listed)CPT|HCPCS

82728	Ferritin
83540	Iron
83550	Iron binding capacity
0024U	Transferrin = Glycosylated acute phase proteins (GlycA), NMR spectroscopy, quantitative (Proprietary test: GlycA; Lab: LabCorp)
0251U	Hepcidin-25, ELISA, serum or plasma (Proprietary test: Intrinsic Hepcidin IDx™, Lab/Manufacturer: IntrinsicDx)

Provider Actions

Documentation Required

Indication required for coverage

Document that testing meets the covered indications listed in this policy. Providers should include clinical indication, relevant signs/symptoms or family history, prior test results when applicable, and timing/specimen details (see RLS guidance). When testing is performed in the setting of inflammation, document adjunct test results (e.g., CRP, ESR) and clinical context to support interpretation of ferritin and adjunct tests.

Examples of required documentation: clinical note showing anemia evaluation, symptoms of hemochromatosis, first-degree relative with hereditary hemochromatosis, liver disease workup, HLH/Still Disease evaluation, CKD status (including dialysis), iron therapy start/changes, or RLS/periodic limb movement disorder evaluation.
If inflammatory state is present (infection, autoimmune disease, recent surgery, malignancy), document CRP or other inflammatory markers and rationale for using ferritin/adjunct tests given ferritin’s acute-phase reactant properties.
For preoperative anemia evaluation, document surgery type and timing, hemoglobin/CBC, and that iron studies (ferritin ± TSAT) are being used to guide perioperative anemia management.

Background and Guideline Summary

Background: Iron metabolism is tightly regulated to maintain systemic homeostasis. Dietary iron is absorbed by enterocytes, transported bound to transferrin, and stored intracellularly in ferritin. Hepcidin, a small peptide hormone, modulates serum iron by binding ferroportin and promoting its degradation, thereby reducing iron export. Ferritin is both an intracellular iron storage protein and an acute phase reactant that can be elevated by inflammation, infection, liver disease, renal failure, metabolic syndrome, or malignancy, which can complicate interpretation of serum ferritin when assessing iron stores.

Clinical context and tests: Serum ferritin is the most commonly used clinical metric to assess iron stores and is sensitive for iron deficiency at low thresholds (e.g., <30 μg/L noted as a sensitive indicator), but inflammatory states may mask deficiency and require adjunct tests (CRP, TSAT, reticulocyte hemoglobin, or hepcidin when available). Transferrin saturation (TSAT) is useful to evaluate iron availability and iron overload risk; very high TSAT (>~85%) is associated with non-transferrin-bound iron and toxicity risk. The policy excludes carbohydrate-deficient transferrin as out of scope.

Evidence, analytical validity, and guidelines summary: The document summarizes analytic performance and clinical utility data (e.g., ferritin thresholds, hepcidin assay correlations with LC-MS/MS, GlycA measurement limitations) and summarizes recommendations from multiple professional organizations and consensus statements (for example: AGA, KDIGO/NKF-KDOQI/ISN, WHO, ASH, AASM, ECCO, ICCAMS, AAFP, ASCO/ASH), including key diagnostic and monitoring thresholds and testing frequency guidance for specific clinical situations.

Guideline-based diagnostic and monitoring criteria (summarized)

Recommendations from multiple professional organizations and consensus statements:

ANY of the following

Evidence Summary

Evidence summaries (analytic & guideline findings)

Analytical validity - ferritin low thresholdLow serum ferritin (<30 µg/L) is a sensitive and specific indicator of iron deficiency; ferritin <100 µg/L may indicate deficiency in inflammatory states

AGA recommendationUse ferritin cutoff of 45 ng/mL over 15 ng/mL to diagnose iron deficiency in patients with anemia (strong recommendation, high‑quality evidence)

Hepcidin assay performanceELISA correlates with LC‑MS/MS (r=0.89); HPLC/MS/MS methods report intra‑day CVs <3% and inter‑day CVs <6%

KDIGO 2024 guidanceFor CKD patients treated with iron: test Hgb, ferritin, TSAT every 3 months (non‑dialysis) and monthly for hemodialysis; withhold iron if ferritin ≥700 ng/mL or TSAT ≥40%

WHO 2020 cutoffsAge- and inflammation‑specific ferritin thresholds provided (e.g., infants 0–23 mo <12 µg/L; adults <15 µg/L healthy; higher cutoffs with inflammation) and overload risk cutoffs (females >150 µg/L, males >200 µg/L)

Revision History

2026-05-15effectiveLatest

Policy effective date updated to 05/15/2026; Clinical Advisory Board meeting and policy review resulted in multiple coverage criteria changes: CC1 overall frequency cap added ('no more than one test per month unless otherwise specified'); CC1.b edited to add frequency 'Once every three weeks for individuals with an iron overload disorder.'; CC1.h edited to include CKD-dependent frequencies (non-dialysis: one test every three months; receiving dialysis: one test every month), with CC1.h.ii renumbered to CC1.i; new CC1.j added for restless legs syndrome/periodic limb movement disorder; CC2.d added for RLS/PLMD; Note 1 updated to align symptoms list.

2025-06-01administrative_revision

Reviewed and updated background, guidelines, and evidence-based references; no changes to coverage criteria but edits for clarity: removed parenthetical language from CC2, edited CC3 to clarify testing of asymptomatic individuals is not allowed, and added new CC4 explicitly excluding serum hepcidin testing.

Policy Summary

Payerblue cross blue shield - louisiana

PolicyG2011 diagnostic testing of iron homeostasis metabolism pdf

Policy CodePolicy AHS - G2011

Change TypeMaterial edits to frequency rules, added indications, and explicit exclusions

Effective DateMay 15, 2026

Next Review Date

Key ActionProviders must document that testing meets one of the listed covered indications and ensure testing frequency follows policy-specified limits.

SourceLink

On This Page

For the evaluation of individuals with liver disease.

For the evaluation of hemophagocytic lymphohistiocytosis (HLH) and Still Disease.

In males with secondary hypogonadism.

For individuals who have chronic kidney disease:

One test every three months if the individual is not receiving dialysis.
CKD non-dialysis frequency limit: once every 3 months.
One test every month if the individual is receiving dialysis.
CKD on dialysis frequency limit: once every month.

For individuals on iron therapy.

For individuals with restless legs syndrome or periodic limb movement disorder.

Measurement of serum transferrin saturation

Measurement of serum transferrin saturation MEETS COVERAGE CRITERIA in any of the following:

ANY of the following

For the evaluation of iron overload in individuals with symptoms of hemochromatosis (see Note 1).
For the evaluation of iron overload in individuals with first-degree relatives (see Note 2) with confirmed hereditary hemochromatosis (HH).
For the evaluation of iron deficiency anemia.
For individuals with restless legs syndrome or periodic limb movement disorder.
CC2.d: Restless legs syndrome (RLS) / periodic limb movement disorder (PLMD) — include clinical context of RLS/PLMD per provider documentation.

Covered when ALL of the following are met: CC1 (Ferritin testing and frequency limits)

Covered when ALL of the following are met: CC1 (Ferritin testing and frequency limits). Indication must meet CC1 subcriteria. Overall frequency cap: no more than one ferritin test per month unless otherwise specified in CC1 subcriteria.

ALL of the following

Indication meets at least one CC1 subcriterion (examples below).
CC1 examples
- CC1.b: Once every three weeks for individuals with an iron overload disorder.
  Frequency override: once every 3 weeks for iron overload disorders.
- CC1.h/i: For individuals who have chronic kidney disease — One test every three months if not receiving dialysis; One test every month if receiving dialysis.
  CKD frequency details included.
- CC1.j: For individuals with restless legs syndrome or periodic limb movement disorder.
Overall frequency limit: No more than one ferritin test per month unless a CC1 subcriterion specifies a different interval (e.g., iron overload disorder or CKD).

Not Medically Necessary / Does NOT Meet Coverage Criteria (CC3 and CC4)

Not Medically Necessary / Does NOT Meet Coverage Criteria

ANY of the following

For all other situations not addressed above, measurement of ferritin or transferrin levels, including transferrin saturation, DOES NOT MEET COVERAGE CRITERIA.
Serum hepcidin testing, including immunoassays, DOES NOT MEET COVERAGE CRITERIA.
The use of GlycA testing to measure or monitor transferrin or other glycosylated proteins DOES NOT MEET COVERAGE CRITERIA.

Serum hepcidin testing, including immunoassays, DOES NOT MEET COVERAGE CRITERIA.

explicit hepcidin exclusion

GlycA exclusion: The use of GlycA testing to measure or monitor transferrin or other glycosylated proteins DOES NOT MEET COVERAGE CRITERIA.

GlycA excluded

Billing Rule

Frequency limits for serum ferritin

General frequency rule for serum ferritin: report no more than one ferritin test per month unless a listed exception applies. Document the clinical reason and timing when exceptions are used.

Iron overload disorders: up to once every 3 weeks.
Chronic kidney disease (not receiving dialysis): once every 3 months.
Chronic kidney disease (receiving dialysis): once monthly.
Restless legs syndrome/periodic limb movement disorder: follow timing guidance — draw in the morning and avoid iron supplements/iron-containing foods for 24 hours prior; document timing of last supplement/meal and specimen collection.

Denial Risk

Denial for non-covered indications

Claims for indications not listed in the covered indications may be denied. Ensure documentation supports a covered indication prior to billing.

Asymptomatic screening (no signs, symptoms, or listed clinical context) is excluded and may be denied.

Billing Rule

Test exclusion: hepcidin

Hepcidin testing does not meet coverage criteria and should not be billed to Blue Cross and Blue Shield of Louisiana as a covered test under this policy.

Proprietary hepcidin assay code referenced: 0251U — do not bill as covered.

Billing Rule

Applicable CPT/HCPCS codes

Report the appropriate CPT/HCPCS code for the specific laboratory test(s) performed.

82728 — Ferritin
83540 — Iron, serum
83550 — Total iron-binding capacity (TIBC) or transferrin
0024U — Transferrin receptor (proprietary LDT/assay code as referenced)
0251U — Proprietary hepcidin code (not covered; see exclusion)

Documentation Required

Timing and specimen handling for RLS testing

For restless legs syndrome (RLS) or periodic limb movement disorder testing, collect specimens in the morning. Patients should avoid iron supplements and iron-containing foods for 24 hours prior to specimen collection; document timing of last supplement/meal and the time of draw in the medical record.

Documentation Required

Monitoring frequency for CKD patients on iron/ESA

For individuals with CKD being treated with iron and/or ESAs, monitor ferritin and TSAT frequently during treatment initiation and periodically after stability to guide therapy and withholding decisions.

When initiating or changing iron therapy or ESA dosing: monitor monthly.
After stable dosing: at least every 3 months for non-dialysis CKD patients.
Hemodialysis patients: monitor monthly.
KDIGO-based withholding thresholds: consider withholding IV iron if ferritin ≥ 700 ng/mL or TSAT ≥ 40%; document values and clinical decision.

Denial Risk

Claims denial for non-covered indications or asymptomatic screening

Testing outside the covered indications or for asymptomatic screening may be denied. Ensure clinical documentation links testing to a listed covered indication before submitting claims.

Asymptomatic individuals without clinical signs/symptoms, family history, CKD, preoperative anemia assessment, inflammatory workup, or other covered indications are excluded and subject to denial.

AGA (iron deficiency diagnosis and management): Use ferritin cutoff of 45 ng/mL over 15 ng/mL to diagnose iron deficiency in patients with anemia45 ng/mL cutoff
AGA recommendation
AGA (iron deficiency diagnosis and management): In inflammatory conditions or CKD, use additional tests (CRP, transferrin saturation, soluble transferrin saturation) with ferritin
AGA comment
AGA (iron deficiency diagnosis and management): Consider every-other-day oral iron dosing; add vitamin C to improve absorption; use IV iron if oral not tolerated or ferritin does not improve; prefer IV formulations that replace deficits in 1-2 infusions
AGA management points
AGA (iron deficiency diagnosis and management): Use IV iron after bariatric surgery and in IBD with impaired absorption or active inflammation
AGA management
ASCO/ASH (cancer-related anemia and ESA use): ESAs generally not recommended for most nonchemotherapy-associated anemia (except selected MDS patients)
ASCO/ASH guideline
ASCO/ASH (cancer-related anemia and ESA use): Baseline and periodic monitoring of iron, TIBC, transferrin saturation, or ferritin recommended when using ESAs
monitoring recommendation
AAFP: Low serum ferritin associated with iron deficiency anemia; older patients with suspected iron deficiency anemia should undergo endoscopy to evaluate for occult GI malignancy; low-dose iron formulations (15 mg elemental iron) may be effective and better tolerated
AAFP points
ACG: All patients with abnormal liver chemistries (absent acute hepatitis) should be tested for hereditary hemochromatosis with iron level, transferrin saturation, and serum ferritin
ACG recommendation
WHO (ferritin cutoffs): Ferritin cutoffs for iron deficiency and overload by age group and inflammation status as per WHO guidanceWHO age/inflammation-specific cutoffs
WHO 2020
ICCAMS / International Consensus perioperative and surgical patients: All patients with anemia should be evaluated early; evaluation should include iron studies: serum iron, TIBC, TSAT, ferritin; absolute iron deficiency: ferritin <30 ng/mL and/or TSAT <20%; ferritin <100 ng/mL may define iron deficiency in inflammatory statesferritin <30 ng/mL and/or TSAT <20%
ICCAMS criteria
ECCO (IBD): Use CBC, serum ferritin, CRP for screening; monitor every 6-12 months in remission/mild disease and at least every 3 months in active disease; ferritin <30 µg/L indicates iron deficiency in remission; ferritin up to ~100 µg/L may still indicate deficiency in active inflammationmonitoring intervals and ferritin thresholds
ECCO guidance
ASH (iron overload monitoring): Serum ferritin used to monitor iron chelation therapy; check frequently (every 3-6 weeks) to calculate running averages due to variability; transferrin saturation >85% risks NTBIevery 3-6 weeks
ASH monitoring guidance
KDIGO / NKF-KDOQI / ISN (CKD): Recommend serum ferritin and TSAT to define iron stores and availability; test prior to initiation of treatment, monthly during initial treatment, and at least every 3 months after stable hemoglobin; 2024 KDIGO: test hemoglobin, ferritin, TSAT every 3 months for non-dialysis CKD patients treated with iron and monthly for hemodialysis; withhold iron if ferritin ≥700 ng/mL or TSAT ≥40%ferritin ≥700 ng/mL or TSAT ≥40% to withhold iron
KDIGO 2024
AASM (restless legs syndrome): In clinically significant RLS, regularly test serum iron studies including ferritin and TSAT; supplement iron if ferritin ≤75 ng/mL or TSAT <20%; only IV if ferritin between 75-100 ng/mL; draw in morning avoiding iron supplements/foods for 24 hoursferritin ≤75 ng/mL or TSAT <20%
AASM guidance
Government of British Columbia (monitoring response to oral iron): Reassess moderate-severe anemia by CBC as early as 2-4 weeks; hemoglobin should increase by 10-20 g/L by 4 weeks; continue iron therapy additional 4-6 months after correction; re-check ferritin 3-6 months after normalization; target ferritin >100 µg/Ltarget ferritin >100 µg/L
BC monitoring

Definitions (term → definition)

First‑degree relativesParents, full siblings, and children of the individual

Symptoms of hemochromatosisFatigue; arrhythmias; joint pain; low libido/erectile dysfunction; pain in index/middle finger knuckles; skin darkening; unexplained weight loss; upper abdominal pain

TSATTransferrin saturation calculated from serum iron and total iron binding capacity

NTBINon‑transferrin‑bound iron that circulates when TSAT exceeds ~85% and is associated with toxicity risk

LPILabile plasma iron, a subset of NTBI associated with Fenton reactions; research metric

Note 2 clarificationFirst‑degree relatives include parents, full siblings, and children of the individual

Multiple peer‑reviewed studies and clinical guidelines supporting diagnostic utility and testing frequencies (references listed throughout policy)

2024-05-01administrative_revision

Background, guidelines, and references updated; literature review did not necessitate modifications to coverage criteria.

2023-03-10administrative_revision

Updated background, guidelines, and evidence references; edits for clarity to CC1, CC2, and CC3 and added Note 2 defining first-degree relatives.

2022-05-15original_effective

Initial policy implementation (original effective date 05/15/2022).